Combining nortriptyline and morphine provides better pain relief than using either drug alone, according to a new study

Easing the pain

 

(April 7, 2015) – The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen’s. Combining morphine, a narcotic pain reliever, and nortriptyline, an antidepressant, has been found to successfully relieve chronic neuropathic pain – or a localized sensation of pain due to abnormal function of the nervous system – in 87 per cent of patients, and significantly better than with either drug alone.


"Chronic pain is an increasingly common problem and can exert disastrous personal, societal, and socio-economic impacts on patients, their families, and their communities," says Ian Gilron, lead author of the study. "Current neuropathic pain treatments are ineffective or intolerable for many sufferers so this new evidence supporting the morphine-nortriptyline combination is important news for patients."

 

During the study, average daily pain was measured using a patient’s numerical rating of pain on a validated scale from 0 – 10. It was found that average daily pain before treatment was 5.6, which dropped to 2.6 when the patient was receiving the drug combination. On average, patients taking nortriptyline and morphine alone rated their pain at 3.1 and 3.4, respectively.

 

It was also found that common side effects for both drugs, which can include constipation and dry mouth, did not worsen during the combination treatment.

 

"It’s important to remember that we don’t want to completely eliminate patients’ ability to sense pain as it’s a warning system for us, but we do want to find the right balance of pain relief and drug side effects," says Dr. Gilron, a professor in Queen’s School of Medicine and anesthesiologist at Kingston General Hospital. "Morphine and nortriptyline are excellent candidates for pain management because of the extensive research conducted on them, their low cost, and widespread availability all over the world."

 

In the double-blind, randomized crossover study, every patient had the opportunity to try every one of the three treatments: the combination, morphine alone and nortriptyline alone in each of the three six-week treatment periods. Throughout each treatment period, patients attended follow-up assessments to record their pain levels and side effects.

Werbung

 

This research was published in PAIN, the highest impact pain journal globally.

 


Queen’s University, 07.04.2015 (tB).

MEDICAL NEWS

Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds
Monoclonal antibody therapy for COVID-19 safe, effective for transplant patients
Having trouble falling asleep predicts cognitive impairment in later life
SARS-CoV-2 detectable — though likely not transmissible — on hospital…

SCHMERZ PAINCARE

Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern
Wenn Schmerzen nach einer OP chronisch werden

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…

ONKOLOGIE

Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung
Risikobasiertes Brustkrebs-Screening kosteneffektiv
Krebs – eine unterschätzte finanzielle Herausforderung

MULTIPLE SKLEROSE

Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose
Patienteninformationen zu Interferon-beta-Präparaten
Zulassung des S1P Modulators Ponesimod zur Behandlung von erwachsenen Patienten…

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung